epoetin beta pegol
Recently Published Documents


TOTAL DOCUMENTS

33
(FIVE YEARS 4)

H-INDEX

5
(FIVE YEARS 1)

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Takahide Iwasaki ◽  
Akira Fujimori ◽  
Takeshi Nakanishi ◽  
Shioko Okada ◽  
Nobuto Hanawa ◽  
...  

Abstract Background Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a factor that regulates hepcidin. In addition, fibroblast growth factor 23 (FGF23), which has been recognized as a phosphorus-regulating hormone, appears to be involved in haematopoietic regulation. Clarification of the detailed mechanism of haematopoiesis could lead to the improvement of renal anaemia treatment. Methods Epoetin beta pegol (CERA) was administered to patients undergoing haemodialysis at week 0, and the same amount of CERA with saccharated ferric oxide (SFO) was administered at week 4. The changes in haematopoiesis-related biomarkers, including ERFE, intact FGF23 (iFGF23), C-terminal FGF23 (cFGF23), and inflammatory markers, were examined. Results Administration of CERA increased ERFE levels, decreased hepcidin levels, and stimulated iron usage for haematopoiesis, leading to an increase in reticulocytes (Ret) and haemoglobin (Hb). Simultaneous administration of SFO with CERA (CERA + SFO) significantly attenuated the responses of ERFE, Ret, and Hb compared with CERA alone. Although iFGF23 levels were not affected by either CERA or CERA + SFO, cFGF23 was significantly elevated from baseline after CERA. Since cFGF23 levels were not affected by CERA + SFO, cFGF23 levels after CERA + SFO were significantly lower than those after CERA alone. The ratio of iFGF23 to cFGF23 (i/cFGF23 ratio) was significantly higher after CERA + SFO than that after CERA alone. In addition, high-sensitivity C-reactive protein (hsCRP) levels were significantly higher after CERA + SFO than after CERA alone. Conclusion Administration of SFO suppressed haematopoietic responses induced by CERA. Elevation of i/cFGF23 ratio and hsCRP could account for the inhibitory effects of SFO on haematopoiesis. Trial registration This study was registered with the University Hospital Medical Information Network (ID UMIN000016552).



2021 ◽  
pp. 1-10 ◽  
Author(s):  
Masaomi Nangaku ◽  
Takayuki Hamano ◽  
Tadao Akizawa ◽  
Yoshiharu Tsubakihara ◽  
Reiko Nagai ◽  
...  

<b><i>Background:</i></b> Daprodustat is an oral agent that stimulates erythropoiesis by inhibiting the prolyl hydroxylases which mark hypoxia-inducible factor for degradation through hydroxylation. Its safety and efficacy (noninferiority) were assessed in this 52-week, open-label study. <b><i>Methods:</i></b> Japanese patients not on dialysis (ND) (<i>N</i> = 299) with anemia of CKD (stages G3, G4, and G5) with iron parameters of ferritin &#x3e;100 ng/mL or transferrin saturation &#x3e;20% at screening were randomized to daprodustat or epoetin beta pegol (continuous erythropoietin receptor activator [CERA], also known as methoxy polyethylene glycol-epoetin beta). After initiation of the study, the daprodustat starting dose for erythropoiesis-stimulating agent (ESA)-naïve participants was revised, and daprodustat was started at 2 or 4 mg once daily depending on baseline hemoglobin. ESA users switched to daprodustat 4 mg once daily. CERA was started at 25 μg every 2 weeks for ESA-naïve patients and 25–250 μg every 4 weeks for ESA users based on previous ESA dose. In both treatment groups, dose was adjusted every 4 weeks based on hemoglobin level and changed according to a prespecified algorithm. The primary endpoint was mean hemoglobin level during weeks 40–52 in the intention-to-treat (ITT) population. ESA-naïve patients who entered before the protocol amendment revising the daprodustat starting dose were excluded from the ITT population. <b><i>Results:</i></b> Mean hemoglobin levels during weeks 40–52 were 12.0 g/dL in the daprodustat group (<i>n</i> = 108; 95% confidence interval [CI], 11.8–12.1) and 11.9 g/dL for CERA (<i>n</i> = 109; 95% CI 11.7–12.0); the difference between the groups was 0.1 g/dL (95% CI −0.1 to 0.3 g/dL). The lower limit of the 95% CI of the difference was greater than the prespecified margin of −1.0 g/dL. The mean hemoglobin level was within the target range (11.0–13.0 g/dL) during weeks 40–52 for 92% of participants in both groups. There was no meaningful difference in the frequencies of adverse events. <b><i>Conclusions:</i></b> Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. Daprodustat was well tolerated, with no new safety concerns identified.



2021 ◽  
Author(s):  
Takahide Iwasaki ◽  
Takeshi Nakanishi ◽  
Shioko Okada ◽  
Nobuto Hanawa ◽  
Yukiko Hasuike ◽  
...  

Abstract Background: Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a factor that regulates hepcidin. In addition, fibroblast growth factor 23 (FGF23), which has been recognized as a phosphorus-regulating hormone, appears to be involved in haematopoietic regulation. Clarification of the detailed mechanism of haematopoiesis could lead to the improvement of renal anaemia treatment.Methods: Epoetin beta pegol (CERA) was administered to patients undergoing haemodialysis at week 0, and the same amount of CERA with saccharated ferric oxide (SFO) was administered at week 4. The changes in haematopoiesis-related biomarkers, including ERFE, intact FGF23 (iFGF23), C-terminal FGF23 (cFGF23), and inflammatory markers, were examined.Results: Administration of CERA increased ERFE levels, decreased hepcidin levels, and stimulated iron usage for haematopoiesis, leading to an increase in reticulocytes (Ret) and haemoglobin (Hb). Simultaneous administration of SFO with CERA (CERA + SFO) significantly attenuated the responses of ERFE, Ret, and Hb compared with CERA alone. Although iFGF23 levels were not affected by either CERA or CERA + SFO, cFGF23 was significantly elevated from baseline after CERA. Since cFGF23 levels were not affected by CERA + SFO, cFGF23 levels after CERA + SFO were significantly lower than those after CERA alone. The ratio of iFGF23 to cFGF23 (i/cFGF23 ratio) was significantly higher after CERA + SFO than that after CERA alone. In addition, high-sensitivity C-reactive protein (hsCRP) levels were significantly higher after CERA + SFO than after CERA alone.Conclusion: Administration of SFO suppressed haematopoietic responses induced by CERA. Elevation of i/cFGF23 ratio and hsCRP could account for the inhibitory effects of SFO on haematopoiesis.This study was registered with the University Hospital Medical Information Network (ID UMIN000016552).



2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Yasuki Shingu ◽  
Tomohiro Nakata ◽  
Shinji Sawai ◽  
Hisaya Tanaka ◽  
Osamu Asai ◽  
...  


2020 ◽  
Author(s):  
Yukiko Yasuoka ◽  
Takashi Fukuyama ◽  
Yuichiro Izumi ◽  
Tetsuro Yamashita ◽  
Yushi Nakayama ◽  
...  

Abstract Doping tests for illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. Here, we show a new Western blotting to distinguish endogenous erythropoietin (Epo, 35-38 kDa) and exogenous ESAs (epoetin alpha and beta; 38-42 kDa, darbepoetin alpha; 47-50 kDa, epoetin beta pegol; 93-110 kDa). In contrast, Liquid Chromatography/Mass Spectrometry analyzed all endogenous Epo and exogenous ESAs as delycosylated 22 kDa Epo, indicating that LC/MS analysis could not distinguish Epo and ESAs. We believe that our Western blotting is useful to protect against illegal use of ESAs.





2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Ken Aizawa ◽  
Ryohei Kawasaki ◽  
Yoshihito Tashiro ◽  
Yasushi Shimonaka ◽  
Michinori Hirata




Sign in / Sign up

Export Citation Format

Share Document